Michael Makris։ New NEJM Paper Reports Results of Mim8 in Hemophilia A
Michael Makris, Emeritus Professor of Haemostasis and Thrombosis at University of Sheffield, shared a post on LinkedIn about a recent article by Maria Elisa Mancuso et al, published in The New England Journal of Medicine (NEJM), adding։
”The Mim8 results paper was published today in the New England Journal of Medicine.
Mim8 works in the same way and is a direct competitor to emicizumab (Hemlibra).
The introduction of emicizumab has been the most impactful change in hemophilia care in the last 20-25 years.
Both Mim8 and emicizumab are bispecific antibodies. Is one better than the other in terms of efficacy? Only a randomised trial will tell us this, but nobody will do such a trial. I expect there will be lots of papers comparing the two products in a non-randomised way, with all the limitations that they bring.
In most countries, the introduction of a second similar drug will result in competition and lower prices, but I doubt this will be the case in the US.
The PDF of the paper is behind a paywall, but here is the graphical summary.”
Title: Mim8 Bispecific Antibody Prophylaxis in Hemophilia A with or without Inhibitors
Authors: Maria Elisa Mancuso, Anthony K.C. Chan, Chandrakala Shanmukhaiah, Chuhl Joo Lyu, Joanna Zdziarska, Johnny Mahlangu, Lize F.D. van Vulpen, Pratima Chowdary, Renchi Yang, Steven R. Lentz, Tadashi Matsushita, Wan Hui Ong Clausen, Ilgiz Rakhmatullin, Johannes Oldenburg
Other posts featuring Michael Makris on Hemostasis Today.
-
Sep 18, 2026, 14:52Abdul Muqtadir Abbasi: How Do Hematologists Know Which Coagulation Factor Is the Problem?
-
Sep 18, 2026, 14:48Kato Ramaekers: Redefining Integrin αIIbβ3 in Platelet Formation
-
Sep 18, 2026, 14:33Heghine Khachatryan: The discussion of Thrombophilia, APS and Coagulation Testing
-
Sep 18, 2026, 14:27Maria Cherska: Are We Overlooking the Spleen in Cardiometabolic Research?
-
Sep 18, 2026, 14:05Wolfram Ruf: Managing Thrombotic Risk in Pregnancy
-
Sep 18, 2026, 13:38Sam Tsimikas: Uncovering a Modifiable Lp(a) Phenotype in Hypertriglyceridemia
-
Sep 18, 2026, 13:22Christine Rabinak: Predictive Modeling for Individualized Unfractionated Heparin Dosing
-
Sep 18, 2026, 13:07Bastu Odoka: Principles of Pediatric Transfusion Dosing
-
Sep 18, 2026, 12:54David McIntosh: Plasma Therapies and the Unfinished Global Access Mission